Actively Recruiting
Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency
Led by Université de Sherbrooke · Updated on 2026-02-10
16
Participants Needed
1
Research Sites
381 weeks
Total Duration
On this page
Sponsors
U
Université de Sherbrooke
Lead Sponsor
I
Institut de Recherches Cliniques de Montreal
Collaborating Sponsor
AI-Summary
What this Trial Is About
Lipoprotein lipase (LPL) is an enzyme that plays an important role in removing triglycerides (TG) (molecules that transport dietary fat) from the blood. Patients with LPL deficiency (LPLD) display during their whole life very high plasma TG levels often associated with episodes of postprandial abdominal pain, malaise, blurred vision, dizziness (hyperchylomicronemia syndrome) that may lead to recurrent pancreatitis episodes. Because of their very slow clearance in blood of their chylomicron-TG, these patients need to severely restrict their dietary fat intake to avoid these complications. Fortunately, novel treatments are being developed to circumvent LPL deficiency (LPLD) metabolic effect on chylomicron-TG clearance. However, there is no data on how LPLD affect organ-specific dietary fatty acid metabolism nor how the novel therapeutic agents may change this metabolism. For example, it is currently not understood how subjects with LPLD store their DFA into adipose tissues and whether they are able to use DFA as a fuel to sustain their cardiac metabolism, as healthy individuals do. This study aims to better understand theses two questions.
CONDITIONS
Official Title
Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years
- 8 healthy individuals with lipoprotein lipase deficiency confirmed by gene mutation and history of fasting triglycerides over 5 mmol/l
- 8 control subjects with normal fasting glucose, normal glucose tolerance, normal HbA1c, and fasting triglycerides below 1.5 mmol/l
- Willing and able to follow the study protocol
- Signed informed consent acknowledging understanding of the study purpose
You will not qualify if you...
- Age under 18 years
- Known cardiovascular disease or abnormal ECG
- Treatment with drugs affecting lipid or carbohydrate metabolism such as fibrates, thiazolidinediones, or beta-blockers (except statins, metformin, and certain antihypertensives that can be stopped safely)
- Treatment with anti-hypertensive medication (for LPL-deficient individuals only)
- Presence of liver or kidney disease or uncontrolled thyroid disorder
- Previous diagnosis of heparin-induced thrombocytopenia
- Use of oral anticoagulants or platelet aggregation inhibitors
- History of major bleeding events
- Smoking more than 1 cigarette per day or consuming more than 2 alcoholic drinks per day
- Female of childbearing potential who is pregnant, breastfeeding, planning pregnancy, or with a positive pregnancy test at enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre de recherche du CHUS
Sherbrooke, Quebec, Canada, J1H 5N4
Actively Recruiting
Research Team
F
Frédérique Frisch
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here